All In Biotech

Drug Trial Radar · NCT01869556

Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress

Comparison of Intravenous Ergonovine With Intramuscular Carboprost, Both in Combination With Oxytocin Infusion, During Cesarean Section for Failure to Progress in Labor: A Double-blinded Placebo-controlled Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jun 4, 2013

Primary completion

Jul 8, 2019

Study completion Sep 30, 2019

Sponsor

Lead sponsor
Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 14 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Patients having Cesarean section after they have been in labor for many hours bleed much more, in average twice as much, as compared with patients having an elective Cesarean section. The investigators believe a simple change in practice might contribute to reduce this bleeding. This study will involve the use of oxytocin (also known as syntocinon), ergonovine (also known as ergot) and carboprost (also known as hemabate). Oxytocin is routinely used to help contract the uterus and keep it contracted after the delivery of the baby and placenta, so as to reduce the amount of blood loss. Ergonovine is also given through the intravenous line, while carboprost is given as an injection in the muscle. Although they are not routinely given in every case, these are very frequently given as rescue medications to patients who fail to respond appropriately to oxytocin. This study is designed to determine if ergonovine or carboprost given in association with oxytocin, in a preventive way, after delivery of the baby and placenta, can reduce the amount of blood loss during Cesarean sections following a trial of labour.

Conditions

  • Postpartum Hemorrhage

Interventions

  • OxytocinDrug

    Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours

  • ErgotDrug

    Ergot 0.25mg IV

  • CarboprostDrug

    Carboprost 0.25mg IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Need for additional uterotonics intraoperativelyTime frame: 1 hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.